Ralph Bates Pancreatic Cancer Research Fund

EQS-News: Defence Therapeutics Inc.: DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCER

Retrieved on: 
Saturday, June 10, 2023
Transfer, Survival rate, Pancreatic cancer, ARM, Cancer, Microsoft Exchange Server, Animal, Ralph Bates Pancreatic Cancer Research Fund, Melanoma, China International Technology Transfer Center, Neoplasm, Mortality, Research, Therapy, Disease, A1, Vaccine, Defense

Based on these impressive data, Defence contracted Transbiotech Biotechnology Research and Transfer Center, to test the potency of its ARM vaccine in animals with pre-established pancreatic tumors.

Key Points: 
  • Based on these impressive data, Defence contracted Transbiotech Biotechnology Research and Transfer Center, to test the potency of its ARM vaccine in animals with pre-established pancreatic tumors.
  • Therefore, developing a cancer vaccine capable of eradicating this disease will be a major leap in the global fight against cancer.
  • A successful treatment of pancreatic cancer with the ARM vaccine would certainly widen the application of this therapy to other “hard to treat” cancers," says Mr. Plouffe, CEO and president of Defence.
  • According to Hirshberg Foundation for Pancreatic Cancer Research, pancreatic cancer has the highest mortality rate of all major cancers.